替格瑞洛联合二丁酰环磷腺苷钙治疗心律失常的疗效及其对血清Gal-3与CD40L水平的影响  

Efficacy of ticagrelor combined with calcium dibutyrylcyclic adenosine monophosphatein the treatment of arrhythmia and its impact on serum Gal-3 and CD40L levels in patients

作　　者：王成 陈振岭[1] 张翠翠 WANG Cheng;CHEN Zhen-ling;ZHANG Cui-cui(Department of Cardiovascular Medicine,Wanbei Coal-Electricity Group General Hospital,Suzhou 234000,Anhui,China)

机构地区：[1]皖北煤电集团总医院心血管内一科,安徽宿州234000

出　　处：《川北医学院学报》2024年第6期834-838,共5页Journal of North Sichuan Medical College

摘　　要：目的:探讨替格瑞洛联合二丁酰环磷腺苷钙治疗心律失常的疗效及其对患者血清半乳糖凝集素3(Gal-3)、白细胞分化抗原40配体(CD40L)水平的影响。方法:将104例心律失常患者按照治疗方式不同分为对照组和研究组,每组各52例。对照组患者采用二丁酰环磷腺苷钙治疗;研究组采用替格瑞洛联合二丁酰环磷腺苷钙治疗,两组均治疗2个月。比较两组患者治疗前后心功能[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左心室舒张末期直径(LVEDD)]、心肌损伤标志物[心肌肌钙蛋白T(cTnT)、肌酸激酶同工酶(CK-MB)、N末端脑钠肽前体(NT-proBNP)]、炎症因子[肿瘤坏死因子ɑ(TNF-ɑ)、高敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)]、半乳糖凝集素3(Gal-3)、肿瘤坏死因子相关激活蛋白(CD40L)、血管内皮功能[一氧化氮(NO)、内皮素1(ET-1)]及临床疗效。结果:治疗后,两组LVEF、NO水平均升高,且研究组高于对照组(P<0.05);两组LVESD、LVEDD、cTnT、CK-MB、NT-proBNP、TNF-ɑ、hs-CRP、IL-6、Gal-3、CD40L、ET-1水平均降低,且研究组低于对照组(P<0.05)。研究组临床疗效高于对照组(P<0.05)。结论:替格瑞洛与二丁酰环磷腺苷钙联合治疗,可改善心律失常患者心功能,减轻心肌损伤程度,提高临床疗效,加速恢复,疗效较显著。Objective:To explore the efficacy of ticagrelor combined with calcium dibutyrylcyclic adenosine monophosphate in the treatment of arrhythmia and its impact on the serum levels of Gal-3 and CD40L in patients.Methods:104 patients with arrhythmia weredivided into a control group and a study group according to different treatment methods,with 52 cases in each group.The control group was treated with calcium dibutyryl cyclic adenosine monophosphate for 2 months,while the study group was treated with ticagrelor combined with calcium dibutyryl cyclic adenosine monophosphate for 2 months.The heart function[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)],myocardial injury markers[cardiac troponin T(cTnT),creatine kinase isoenzyme(CK-MB),N-terminal brain natriritic peptide precursor(NT proBNP)],inflammatory factors[tumor necrosis factorɑ(TNF-ɑ),high sensitivity C-reactive protein(hs-CRP)and interleukin-6(IL-6)],Gal-3,CD40L,endothelial function[nitric oxide(NO),endothelin-1(ET-1)],and clinical efficacy before and after treatment were compared between the two groups.Results:After treatment,the LVEF and NO levels increased in both groups,and the study group was higher than the control group(P<0.05).The levels of LVESD,LVEDD,cTnT,CK-MB,NT-proBNP,TNF-ɑ,hs-CRP,IL-6,Gal-3,CD40L and ET-1 decreased in both groups,and the study group was lower than the study group(P<0.05).The clinical efficacy of the study group was higher than that of the control group(P<0.05).Conclusion:The combination therapy of ticagrelor and calcium dibutyryl cyclic adenosine monophosphate can improve the cardiac function of patients with arrhythmia,reduce the degree of myocardial Injury,improve clinical efficacy,promote patient recovery,and achieve good results.

关 键 词：心律失常 替格瑞洛 二丁酰环磷腺苷钙 半乳糖凝集素3 白细胞分化抗原40配体 

分 类 号：R541.7[医药卫生—心血管疾病]